Key facts
- This page summarizes Eric M. Dube's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Feb 2025, 20:30.
Eric M. Dube - 31 Jan 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- TVTX
- Reported as of
- 31 Jan 2025
- Net transaction value
- -$1,024,343
- SEC form
- 4
- Accepted by SEC
- 04 Feb 2025, 20:30:21 UTC
- Prior SEC filing
- 23 Jan 2025
- Next SEC filing
- 12 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric M. Dube filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 04 Feb 2025.
Change
- Previous filing in this sequence was filed on 23 Jan 2025.
- Current net transaction value: -$1,024,343.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TVTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +130,000
- Change %
- +37%
- Price
- $0.000000
- Shares after
- 481,239
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
TVTX
transaction
Common Stock
Sale
- Transaction value
- $1,024,343
- Shares
- -50,691
- Change %
- -11%
- Price
- $20.21
- Shares after
- 430,548
- Date
- 03 Feb 2025
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TVTX
transaction
Derivative
Employee stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +260,000
- Change %
- Price
- $0.000000
- Shares after
- 260,000
- Date
- 31 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 260,000
- Exercise price
- $20.46
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
Footnote F2
This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
Footnote F3
The weighted average sale price for the transaction reported was $20.2076, and the range of prices were between $19.76 and $20.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
Footnote F4
One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.